The device is intended for anyone aged 18 years and up who do not use insulin or those without diabetes who want to learn how diet can impact blood sugar levels.
The FDA has cleared the Dexcom Stelo Glucose Biosensor System, an integrated continuous glucose monitor (CGM), for marketing as the first over-the-counter (OTC) CGM for anyone aged 18 years and up, the federal agency stated in a press release.1
According to the FDA, the device is intended for anybody who does not use insulin or those without diabetes who want to understand how diet could impact blood sugar levels.1
The device, to be the first glucose biosensor cleared for use in the United States without a prescription, features a sensor to be worn on the back of the upper arm.2
The system is not intended for individuals with low blood sugar, or hypoglycemia, as the system is not designed to alert users to the condition.1
The system uses a wearable sensor to go along with a smartphone application that continually measures, records, analyzes, and displays glucose levels. Blood glucose measurements and trends are presented in the app every 15 minutes.1
Users can wear the sensor for up to 15 days before replacing.1
“CGMs can be a powerful tool to help monitor blood glucose," said Jeff Shuren, MD, JD, director, Center for Devices and Radiological Health, FDA. "Today’s clearance expands access to these devices by allowing individuals to purchase a CGM without the involvement of a health care provider."1
The FDA received data from a clinical study demonstrating the device "performed similarly to other integrated CGMs, with adverse events reported such as local infection, skin irritation, and pain or discomfort.1
“Giving more individuals valuable information about their health, regardless of their access to a doctor or health insurance, is an important step forward in advancing health equity for U.S. patients,” added Shuren.1
According to Dexcom, there are approximately 25 million people living in the United States who live with type 2 diabetes but do not use insulin.2
Starting in the summer of 2024, Stelo will be available for purchase online and without a prescription.2
References:
1. FDA clears first over-the-counter continuous glucose monitor. FDA. Press release. March 5, 2024. Accessed March 6, 2024. https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor
2. Stelo by Dexcom first glucose biosensor cleared by FDA as over-the-counter. Dexcom. Press release. March 5, 2024. Accessed March 6, 2024. https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx
Twiist automated insulin delivery system FDA cleared for children 6 years and up with T1D
March 18th 2024Integrated data from a continuous glucose monitoring device (CGM) and an insulin pump to automate insulin delivery allow AID systems to manage patient blood sugar levels more "effectively," according to Sequel.
Higher burden of care associated with loneliness in caregivers of children with type 1 diabetes
January 4th 2024Results demonstrated that caregiver burden scored a 2.14 on the caregiver burden scale, which is within the average burden level, though a higher burden of care is associated with a higher sense of loneliness. These results can help health care professionals develop a family-centered treatment plan.
Maternal study satisfaction enhances visit compliance in children at risk for diabetes
December 21st 2023A study in the European Journal of Medical Research revealed that higher maternal study satisfaction, older maternal age, and paternal participation were linked to better compliance in visits for children at risk of type 1 diabetes.